

# Resource Summary Report

Generated by PRECISE-TBI on Aug 4, 2026

## Experimental Pharmacology and Oncology Berlin-Buch

RRID:SCR\_003954

Type: Tool

---

### Proper Citation

Experimental Pharmacology and Oncology Berlin-Buch (RRID:SCR\_003954)

---

### Resource Information

**URL:** <http://www.epo-berlin.com/>

**Proper Citation:** Experimental Pharmacology and Oncology Berlin-Buch (RRID:SCR\_003954)

**Description:** A small and medium-sized enterprise (SME) that has expertise in preclinical pharmacology, pharmacokinetics, and toxicology for the characterization of novel anticancer therapeutics and predictive biomarkers like: cytostatics, biologicals (peptides, antibodies), (anti)-hormones, immunomodulators (cytokines), and gene therapeutics. EPO has modern laboratories licensed for animal experiments and gene technology (S2) and a broad panel of murine and human tumor models growing in immunocompetent (SPF-quality, syngeneic strains) or immunodeficient mice (nude, SCID, NOD/SCID). EPO has established imaging technologies to monitor in vivo tumor growth.

**Abbreviations:** EPO

**Synonyms:** EPO - Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology Berlin-Buch, Experimental Pharmacology & Oncology Berlin-Buch GmbH, EPO Berlin-Buch GmbH, EPO-GmbH

**Resource Type:** commercial organization

**Keywords:** tumor model, pharmaceutical, oncology, in vitro, in vivo, antitumor, preclinical, pharmacology, pharmacokinetics, toxicology, anticancer, therapeutic, biomarker, imaging, testing, validation, target

**Related Condition:** Tumor, Cancer

**Resource Name:** Experimental Pharmacology and Oncology Berlin-Buch

**Resource ID:** SCR\_003954

**Alternate IDs:** nlx\_158355

**Record Creation Time:** 20220129T080221+0000

**Record Last Update:** 20260801T190228+0000

---

## Ratings and Alerts

No rating or validation information has been found for Experimental Pharmacology and Oncology Berlin-Buch.

No alerts have been found for Experimental Pharmacology and Oncology Berlin-Buch.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [PRECISE-TBI](#) .

Sch??tte M, et al. (2017) Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nature communications, 8, 14262.

Bradford JR, et al. (2016) Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers. Oncotarget, 7(15), 20773.